EcoDrugPlus

Kit Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSODEG00000012738
Gene Symbol: KIT
3 Cross references
265 Possible Orthologues:

Kras Proto-Oncogene, Gtpase

Ensembl ID : ENSODEG00000010412
Gene Symbol: KRAS
3 Cross references
201 Possible Orthologues:

Lck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSODEG00000003693
Gene Symbol: LCK
3 Cross references
120 Possible Orthologues:

Lyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSODEG00000002925
Gene Symbol: LYN
3 Cross references
202 Possible Orthologues:

Mapk Activated Protein Kinase 2

Ensembl ID : ENSODEG00000006464
Gene Symbol: MAPKAPK2
3 Cross references
233 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSODEG00000011587
Gene Symbol: MAPKAPK5
3 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSODEG00000009653
Gene Symbol: MKNK1
2 Cross references
163 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSODEG00000013380
Gene Symbol: MKNK2
3 Cross references
220 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSODEG00000001007
Gene Symbol: MET
3 Cross references
211 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSODEG00000002358
Gene Symbol: MPL
3 Cross references
186 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSODEG00000014793
Gene Symbol: MLST8
3 Cross references
201 Possible Orthologues:

Nadph Oxidase 4

Ensembl ID : ENSODEG00000002022
Gene Symbol: NOX4
3 Cross references
151 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).